摘要
细胞色素P450 2C19(CY2C19)又称为S-美芬妥英羟化酶,它的两个突变型等位基因CYP2C19m1和CYP2C19m2是引起CYP2C19酶活性缺陷的原因,运用等位基因特异扩增法(ASA)对肺癌患者、膀胱癌患者及正常人进行了CYP2C19基因分型研究,以探索CYP2C19酶活性与肺癌、膀胱癌易患性的关系,经过对74例肺癌患者、50例膀胱癌患者和70例对照组的测定。
Cytochrome P450 2C19(CYP2C19, S-mephenytoin hydroxylase) enzyme deficiency was caused by two mutant alleles: CYP2C19ml and CYP2C19m2. An allele-specific amplification based CYP2C19 genotyping method was employed to analyze 74 cases of lung cancer patients, 50 cases of bladder cancer patients and a control group with 70 healthy subjects. It was found that the frequency of poor metabolizers of CYP2C19 was 32.4% in lung cancer group, 4.0% in bladder cancer group and 15.7% in control group. There were extremely statistic differences between control group and experimental groups. Poor metabolisers of CYP2C19 had an increased risk of lung cancer, but had a decreased risk of bladder cancer. It suggested that CYP2C19 is a new tumor-related gene and the enzyme may participate in the inactivation of carcinogens of lung cancer and the activation of procarcinogens of bladder cancer.
出处
《宁波大学学报(理工版)》
CAS
2000年第3期13-15,共3页
Journal of Ningbo University:Natural Science and Engineering Edition
基金
浙江省自然科学基金!(396473)